Compare Stocks: PEN, LNTH, ITGR, and BDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$181.28 +0.9%	$155.05	$127.59 ▼ $187.35	$49.95B	0.19	2.70 million shs	1.52 million shs
ITGR Integer	$125.04 0.0%	$98.11	$62.00 ▼ $126.14	$4.25B	0.61	777,890 shs	1.96 million shs
LNTH Lantheus	$100.68 -0.3%	$104.17	$49.67 ▼ $111.86	$6.57B	-0.03	1.08 million shs	3.93 million shs
PEN Penumbra	$326.18 +0.1%	$318.98	$221.26 ▼ $362.41	$12.85B	0.7	675,239 shs	240,395 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	+1.72%	+5.71%	+18.01%	+21.60%	-7.27%
ITGR Integer	+0.03%	+0.53%	+33.78%	+46.92%	+17.56%
LNTH Lantheus	+0.03%	-0.21%	-4.41%	+4.94%	+76.54%
PEN Penumbra	+0.40%	+0.89%	+2.55%	+0.92%	+35.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$181.28 +0.9%	$155.05	$127.59 ▼ $187.35	$49.95B	0.19	2.70 million shs	1.52 million shs
ITGR Integer	$125.04 0.0%	$98.11	$62.00 ▼ $126.14	$4.25B	0.61	777,890 shs	1.96 million shs
LNTH Lantheus	$100.68 -0.3%	$104.17	$49.67 ▼ $111.86	$6.57B	-0.03	1.08 million shs	3.93 million shs
PEN Penumbra	$326.18 +0.1%	$318.98	$221.26 ▼ $362.41	$12.85B	0.7	675,239 shs	240,395 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	+1.72%	+5.71%	+18.01%	+21.60%	-7.27%
ITGR Integer	+0.03%	+0.53%	+33.78%	+46.92%	+17.56%
LNTH Lantheus	+0.03%	-0.21%	-4.41%	+4.94%	+76.54%
PEN Penumbra	+0.40%	+0.89%	+2.55%	+0.92%	+35.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDX Becton, Dickinson and Company	2.41	Hold	$185.00	2.05% Upside
ITGR Integer	2.07	Hold	$109.86	-12.14% Downside
LNTH Lantheus	2.36	Hold	$108.11	7.38% Upside
PEN Penumbra	2.12	Hold	$367.07	12.54% Upside

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and BDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	BDX Becton, Dickinson and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	BDX Becton, Dickinson and Company	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$195.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$175.00 ➝ $180.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Hold
8/7/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$198.00 ➝ $204.00
8/7/2026	BDX Becton, Dickinson and Company	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$161.00 ➝ $175.00
8/7/2026	BDX Becton, Dickinson and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$161.00 ➝ $170.00
8/6/2026	BDX Becton, Dickinson and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$210.00
8/5/2026	BDX Becton, Dickinson and Company	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$163.00 ➝ $182.00
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/4/2026	ITGR Integer	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDX Becton, Dickinson and Company	$21.84B	2.29	$23.67 per share	7.66	$88.58 per share	2.05
ITGR Integer	$1.84B	2.31	$10.34 per share	12.09	$49.85 per share	2.51
LNTH Lantheus	$1.56B	4.22	$6.37 per share	15.81	$16.43 per share	6.13
PEN Penumbra	$1.40B	9.15	$4.32 per share	75.52	$36.45 per share	8.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDX Becton, Dickinson and Company	$1.68B	$3.32	54.60	13.60	12.47	4.52%	14.84%	6.93%	N/A
ITGR Integer	$102.81M	$3.66	34.16	18.50	2.99	6.97%	12.79%	6.48%	10/22/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.32	18.71	N/A	17.69%	28.10%	14.35%	N/A
PEN Penumbra	$177.69M	$4.07	80.14	52.52	2.01	10.67%	10.50%	8.17%	N/A

Latest PEN, LNTH, ITGR, and BDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q3 2026	BDX Becton, Dickinson and Company	$3.14	$3.23	+$0.09	$1.37	$4.89 billion	$4.98 billion
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	ITGR Integer	$1.38	$1.60	+$0.22	$0.69	$451.07 million	$464.11 million
7/30/2026	Q2 2026	PEN Penumbra	$1.16	$0.88	-$0.28	$0.88	$389.64 million	$390.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDX Becton, Dickinson and Company	$4.20	2.32%	+5.65%	126.51%	53 Years
ITGR Integer	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PEN Penumbra	N/A	N/A	N/A	N/A	N/A

Latest PEN, LNTH, ITGR, and BDX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	BDX Becton, Dickinson and Company	quarterly	$1.05	2.53%	9/9/2026	9/9/2026	9/30/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDX Becton, Dickinson and Company	0.55	0.87	0.51
ITGR Integer	0.75	3.73	2.41
LNTH Lantheus	0.43	3.06	2.89
PEN Penumbra	0.01	5.75	3.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDX Becton, Dickinson and Company	86.97%
ITGR Integer	99.29%
LNTH Lantheus	99.06%
PEN Penumbra	88.88%

Insider Ownership

Company	Insider Ownership
BDX Becton, Dickinson and Company	0.40%
ITGR Integer	1.10%
LNTH Lantheus	1.70%
PEN Penumbra	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDX Becton, Dickinson and Company	72,000	275.54 million	274.44 million	Optionable
ITGR Integer	11,000	33.99 million	33.62 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
PEN Penumbra	4,700	39.39 million	38.25 million	Optionable

PEN, LNTH, ITGR, and BDX Headlines

Recent News About These Companies

TFX vs. PEN: Which Stock Is the Better Value Option?

August 10 at 12:41 PM | zacks.com

Bank of America Corp DE Sells 46,436 Shares of Penumbra, Inc. $PEN

August 9 at 3:43 AM | marketbeat.com

Royal Bank of Canada Decreases Holdings in Penumbra, Inc. $PEN

August 8 at 4:48 AM | marketbeat.com

The Manufacturers Life Insurance Company Sells 65,658 Shares of Penumbra, Inc. $PEN

August 6, 2026 | marketbeat.com

California State Teachers Retirement System Purchases 7,800 Shares of Penumbra, Inc. $PEN

August 3, 2026 | marketbeat.com

Janus Henderson Group PLC Sells 308,844 Shares of Penumbra, Inc. $PEN

August 2, 2026 | marketbeat.com

Sei Investments Co. Trims Stock Holdings in Penumbra, Inc. $PEN

August 2, 2026 | marketbeat.com

Amundi Buys 259,936 Shares of Penumbra, Inc. $PEN

August 1, 2026 | marketbeat.com

Penumbra (NYSE:PEN) Posts Earnings Results, Misses Expectations By $0.27 EPS

July 31, 2026 | marketbeat.com

Why Is Penumbra (NYSE:PEN) In Focus After Its Latest Medical Device Growth Update?

July 31, 2026 | kalkinemedia.comK

Penumbra: Q2 Earnings Snapshot

July 30, 2026 | chron.com

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

July 30, 2026 | prnewswire.com

First Trust Advisors LP Has $24.70 Million Holdings in Penumbra, Inc. $PEN

July 29, 2026 | marketbeat.com

Penumbra (PEN) to Post Quarterly Earnings on Tuesday

July 28, 2026 | marketbeat.com

Polar Asset Management Partners Inc. Purchases New Position in Penumbra, Inc. $PEN

July 28, 2026 | marketbeat.com

85,000 Shares in Penumbra, Inc. $PEN Purchased by Empyrean Capital Partners LP

July 28, 2026 | marketbeat.com

Magnendo raises $18M to advance robotic platform

July 27, 2026 | msn.com

Whitebox Advisors LLC Acquires Shares of 445,001 Penumbra, Inc. $PEN

July 27, 2026 | marketbeat.com

SummitTX Capital L.P. Acquires New Position in Penumbra, Inc. $PEN

July 27, 2026 | marketbeat.com

Sculptor Capital LP Invests $18.72 Million in Penumbra, Inc. $PEN

July 27, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Penumbra, Inc. $PEN

July 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PEN, LNTH, ITGR, and BDX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

$181.28 +1.65 (+0.92%)

Closing price 03:59 PM Eastern

Extended Trading

$181.95 +0.67 (+0.37%)

As of 06:07 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Integer NYSE:ITGR

$125.04 -0.04 (-0.03%)

Closing price 03:59 PM Eastern

Extended Trading

$125.08 +0.04 (+0.03%)

As of 04:22 PM Eastern

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Lantheus NASDAQ:LNTH

$100.68 -0.30 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$100.75 +0.07 (+0.07%)

As of 05:21 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Penumbra NYSE:PEN

$326.18 +0.20 (+0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$326.44 +0.27 (+0.08%)

As of 05:06 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and BDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEN, LNTH, ITGR, and BDX Earnings

Compare Dividends

Latest PEN, LNTH, ITGR, and BDX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEN, LNTH, ITGR, and BDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEN, LNTH, ITGR, and BDX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

Integer NYSE:ITGR

Lantheus NASDAQ:LNTH

Penumbra NYSE:PEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools